Church of PeptidesSearch
The Friday Gospel · September 25, 2026

FDA Approves Onswik

Lilly’s weekly basal insulin joins the U.S. type 2 diabetes market. New obesity-trial results still require careful reading.

Published September 24, 2026 · September 25 editionBy EpistideLast reviewed September 24, 2026
Fictional personification of Insulin holding a gold key in a warmly lit laboratory
Insulin, personified. Fictional artwork accompanying the scientific record. Read the Insulin record →
Opening Sermon · Fiction

Insulin’s calendar

FICTIONAL CONTINUITY: Insulin entered carrying a calendar with six days crossed out. Epistide examined it carefully. “Fewer injections may lighten the pilgrimage,” he said, “but they do not erase the warning lines.”
Regulatory Gospel · Approved human use

A new weekly basal insulin

The FDA approved Onswik (insulin efsitora alfa-gobe), Eli Lilly’s once-weekly basal insulin, to improve glycemic control in adults with type 2 diabetes alongside diet and exercise. Four Phase 3 studies involving more than 3,400 adults supported approval. Onswik achieved A1C reductions noninferior to daily basal-insulin comparators; Lilly expects a U.S. launch in the coming months.

The U.S. prescribing information does not recommend Onswik for type 1 diabetes because severe hypoglycemia is more likely. Its warnings include potentially life-threatening hypoglycemia, medication mix-ups and accidental overdose. U.S. prescribing information, revised September 2026.

Scientific Revelations · Controlled human evidence

Three different stages of evidence

Onswik, approved: The randomized QWINT studies met their A1C noninferiority objectives. Hypoglycemia findings differed across trials: rates were lower with weekly efsitora in QWINT-1 and numerically higher in QWINT-3 and QWINT-4. Once-weekly treatment does not establish universal superiority or reduced risk.

CagriSema, investigational Phase 3: Novo Nordisk reported estimated average weight loss of 12.4% with its lower-dose cagrilintide/semaglutide combination in adults with type 2 diabetes, versus 9.1% with a lower-dose tirzepatide comparator. It reported noninferior blood-sugar reduction. The comparator limits any broader superiority claim. A separate study reportedly showed 21% weight loss compared with placebo. An FDA decision on the weight-management application is expected in the fourth quarter.

Enicepatide, investigational Phase 2: Roche reported average weight loss of 15.5% at the highest tested dose after 48 weeks among adults with overweight or obesity and type 2 diabetes. In the 447-person study, 62% reportedly reached A1C below 5.7%; 2% receiving the drug discontinued because of adverse effects versus none on placebo. Phase 3 studies are planned for 2027.

Human Record · Safety and evidence boundaries

The warning lines remain

Hypoglycemia remains a central insulin hazard. A longer treatment interval does not eliminate monitoring or medication-error concerns. The company-reported CagriSema and enicepatide results do not establish approval, long-term cardiovascular benefit, or outcomes beyond their studied populations.

No material new observational, animal, in-vitro, or retraction item met this edition’s verification threshold. Unsupported online claims were not promoted into evidence.

Market Tithe · Profitide’s ledger

A trial headline and a market reaction

FICTIONAL COMMENT — PROFITIDE: “The market heard ‘once weekly’ and still checked the ticker every minute.”

Confirmed disclosures: Novo Nordisk presented CagriSema data and outlined a possible launch after regulatory review. Novo is its developer, sponsor, and intended commercial rights holder. A specific commercial manufacturer was not identified in this week’s disclosures; the product remains investigational.

Developer and sponsorNovo Nordisk A/S
TickersNVO · NOVO-B
Evidence stagePhase 3 · investigational

Dated market movement: Novo’s U.S.-listed shares were down more than 4% before the September 21 market open. Reuters also reported investor questions about pricing power, dealmaking strategy, and approaching patent expirations.

Editorial inference: Price action cannot be assigned to one trial result. The disclosed comparison used a lower-dose tirzepatide arm and arrived amid broader strategic concerns.

Descriptive market reporting only—not an investment recommendation.

Movements in the Canon

Classification check

No classification change is recommended. The existing Insulin record can gain a product-specific note about FDA-approved once-weekly basal insulin for adults with type 2 diabetes, with Onswik’s type 1 exclusion and hypoglycemia warning kept explicit.

Those Awaiting Canonization

Further evidence required

CagriSema remains an investigational combination awaiting an FDA decision. Enicepatide remains a Phase 2 candidate requiring full reporting, peer review, and Phase 3 confirmation. Neither announcement justifies reclassification.

Further reading

Once-Weekly Insulin: Convenience, Concentration and the Safety Boundary

  1. How insulin efsitora was engineered to last a week
  2. What noninferiority means
  3. Why hypoglycemia varied across QWINT trials
  4. The type 2 indication and type 1 exclusion
  5. Medication-error and persistence-of-effect questions
  6. Whether fewer injections improve real-world adherence
  7. Post-approval evidence needed to judge benefit
Sacred Footnotes

Sources and conflicts

Conflicts: Lilly sponsored QWINT and sells Onswik. Novo sponsored and owns CagriSema; Roche owns enicepatide. The newly reported CagriSema and enicepatide findings are company-reported, and complete peer-reviewed publications of these particular readouts were not identified during this review.

Educational entertainment only. No treatment, dosing, sourcing, purchasing, prescribing, or investment advice is provided.
← Return to the dated archive